Axicabtagene ciloleucel for patients with non-hodgkin lymphoma

Bookmark and Share
Published: 10 Dec 2017
Views: 1752
Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

Dr Neelapu presents, in a press conference at the 2017 ASH annual meeting, data from long term follow up of the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory aggressive non-hodgkin lymphoma.

Watch the interview with Dr Neelapu or read the new story for more.